CARTPT and neoplasm: In an HCC mouse model, mice treated with pre-induced (Dox+) Tet-CD147-CART significantly reduced tumor volume and weight compared with those of mice that received (Dox-) Tet-CD147-CART (26), but in vivo leaking was noticeable.